EP Patent

EP4413976B1 — A new vamorolone preparation exhibiting improved solubility

Assigned to Santhera Pharmaceuticals Schweiz GmbH · Expires 2025-08-13 · 1y expired

What this patent protects

Patent listed against Agamree.

Drugs covered by this patent

Agamree (VAMOROLONE) · Catalyst Pharms

Patent Metadata

Patent number: EP4413976B1
Jurisdiction: EP
Classification: —
Expires: 2025-08-13
Drug substance claim: No
Drug product claim: No
Assignee: Santhera Pharmaceuticals Schweiz GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.